Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

IV nutrition may change blood clotting, large study finds

NCT ID NCT07470385

Knowledge-focused Sponsor: Mimi Tang, PhD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed observational study looked at how intravenous lipid emulsions (fat-containing nutrition given through a vein) affect blood clotting in 6,259 hospitalized patients. Researchers compared clotting tests before and after patients received these emulsions as part of routine care. The goal is to understand any changes in clotting function, which could help guide safer use of IV nutrition in hospitals.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
intravenous lipid emulsions (fat-containing nutrition given through a vein)
What this could lead to
If it shows a clear effect, this could help doctors better understand how IV nutrition affects blood clotting and guide safer use in hospitals.
What could go wrong
This is an observational study, so it can only show links, not cause and effect. Results may be influenced by other factors and may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

6,259 people

The number who actually took part.

Started

May 2025

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Hospitalized patients who received intravenous lipid emulsions as part of routine clinical care.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who received intravenous lipid emulsion therapy for a total duration of ≥ 5 days during hospitalization. * Lipid emulsions include single-bottle lipid emulsion injections and commercially available three-chamber parenteral nutrition admixtures containing lipid emulsions. * Lipid emulsions do not include anesthetic-containing formulations, such as medium- or long-chain triglyceride lipid emulsions used in propofol. Exclusion Criteria: * Patients who underwent major surgery with total blood loss exceeding 500 mL. * Patients with malignant tumors who were receiving radiotherapy, chemotherapy, or immunotherapy during hospitalization. * Patients with long-term use of anticoagulants or other medications known to affect coagulation function. * Patients with active bleeding, any known coagulation or bleeding disorders, autoimmune diseases (e.g., primary immune thrombocytopenia), hematologic diseases (including thrombocytopenic purpura, megaloblastic anemia, aplastic anemia, or hematologic malignancies), or acquired immunodeficiency diseases. * Patients who received blood transfusions during hospitalization. * Patients with incomplete or missing clinical records.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coagulation disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

blood coagulation disease thrombotic disease vascular hemostatic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coagulation disorder Coagulation function

Contacts and locations

Locations

  • Department of Pharmacy, Xiangya Hospital, Central South University

    Changsha, Hunan, 410028, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.